Edmond DE Rothschild Holding S.A. Takes Position in Denali Therapeutics Inc. $DNLI

Edmond DE Rothschild Holding S.A. bought a new position in Denali Therapeutics Inc. (NASDAQ:DNLI) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 165,080 shares of the company’s stock, valued at approximately $4,246,000.

Several other hedge funds have also recently bought and sold shares of DNLI. BlackRock Inc. acquired a new stake in shares of Denali Therapeutics in the second quarter worth $360,759,000. Norges Bank acquired a new position in shares of Denali Therapeutics during the fourth quarter worth $84,525,000. ADAR1 Capital Management LLC boosted its position in Denali Therapeutics by 3,490.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock valued at $35,932,000 after buying an additional 1,819,339 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Denali Therapeutics by 77.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock valued at $63,329,000 after purchasing an additional 1,672,098 shares during the last quarter. Finally, Temasek Holdings Private Ltd boosted its stake in shares of Denali Therapeutics by 30.9% during the 4th quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after buying an additional 1,657,142 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Insider Activity at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the transaction, the insider owned 281,763 shares in the company, valued at approximately $7,063,798.41. This represents a 1.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 9.70% of the company’s stock.

Denali Therapeutics Price Performance

NASDAQ DNLI opened at $25.69 on Thursday. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a 12-month low of $12.58 and a 12-month high of $27.30. The company has a 50 day moving average price of $24.31 and a two-hundred day moving average price of $21.56. The stock has a market capitalization of $4.11 billion, a PE ratio of -9.05 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $2.15 million. During the same period in the prior year, the firm earned ($0.72) earnings per share. As a group, equities analysts predict that Denali Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on DNLI shares. JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a research report on Monday, July 13th. They issued an “overweight” rating and a $29.00 target price for the company. Sanford C. Bernstein reaffirmed a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Deutsche Bank Aktiengesellschaft lifted their target price on Denali Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Morgan Stanley upped their price target on Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Finally, BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Denali Therapeutics in a report on Monday, May 11th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Denali Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.92.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.